Some patients with moderate to severe psoriasis do not respond or cannot be treated with conventional systemic drugs. The development of biological agents targeting tumor necrosis factor alpha (TNFα), interleukin (IL)-17, IL-12 and IL-23 revolutionized the management of those patients. Yet, treatment dissatisfaction and non-adherence are common among patients with psoriasis. There is scarce data in France about patients’ perceptions and experiences with biologic therapies for psoriasis.
Objectives: The objective of this study was to describe patients’ perceptions and experiences with psoriasis in France, addressing communication with physicians, satisfaction with biologics and concerns regarding treatment options.